REMAP-CAP COVID-19 ACE2 RAS Modulation Domain-Specific Appendix Version 1.0 dated 08 November 2020

**Summary**

In this domain of the REMAP-CAP trial, participants meeting platform entry criteria with suspected or microbiological testing confirmed COVID-19 will be randomized to receive one of up to three renin-angiotensin system (RAS) blockade strategies, depending on availability and acceptability, or control:

* No RAS inhibitor (no placebo)
* Angiotensin converting enzyme inhibitor (ACEi)
* Angiotensin II receptor blocker (ARB)
* ARB in combination with DMX-200, a chemokine receptor-2 [CCR2] inhibitor (ARB + DMX-200)

At this participating site the following interventions have been selected within this domain:

* No RAS inhibitor (no placebo)
* Angiotensin converting enzyme inhibitor (ACEi)
* Angiotensin II receptor blocker (ARB)
* ARB in combination with DMX-200, a chemokine receptor-2 [CCR2] inhibitor (ARB + DMX-200)

Is the site participating in the COVID-19 ACE2 RAS Domain? YES / NO (If yes, please also indicate participation in the different states in the table below)

Name site:

Name PI:

Date:

Signature:

This DSA applies to the following states and stratum:

|  |  |  |
| --- | --- | --- |
| Stratum | Pandemic infection suspected or proven (PISOP) | Pandemic infection neither suspected nor proven (PINSNP) |
| Core protocol documents | REMAP-CAP Core Protocol + Pandemic Appendix | REMAP-CAP CoreProtocol |
| Illness Severity State | Moderate State | Severe State | Severe State |
| Interventions specified in this DSA | No RAS inhibitorACEi ARBARB + DMX-200 | No RAS inhibitorACEi ARBARB + DMX-200 | Not available |
| Interventions submitted for approval in thisjurisdiction | * No RAS inhibitor
* ACEi
* ARB
* ARB + DMX-200
 | * No RAS inhibitor
* ACEi
* ARB
* ARB + DMX-200
 | Not available |
| Interventionsoffered at this site |  | Ward |  |  | ICU |  |  | ICU |  | ICU |
|  | * No RAS inhibitor
* ACEi
* ARB
* ARB + DMX-200
 | * No RAS inhibitor
* ACEi
* ARB
* ARB + DMX-200
 | Not available |

CONFIDENTIAL Page 1 of 2

**Angiotensin converting enzyme inhibitor (ACEi) and Angiotensin II receptor blocker (ARB) Choices**





CONFIDENTIAL Page 2 of 2